Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases in men with hormone-refractory prostate cancer
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Start Date
April 1, 2006
Primary Completion Date
October 1, 2009
Completion Date
February 24, 2012
Last Updated
August 29, 2018
1,904
ACTUAL participants
zoledronic acid
DRUG
denosumab
BIOLOGICAL
Lead Sponsor
Amgen
NCT07202273
NCT06987370
NCT06470503
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions